Recombine develops carrier-screening tests that screen for 180 recessive genetic disorders and are priced at $345 each. The company currently processes about 8,000 patient sets per year. It uses Illumina sequencers and emphasizes proprietary software as its primary differentiator. Rather than rebuilding wet-lab automation, Recombine leverages existing automated lab processes and focuses development on computational analysis. The team plans to move beyond single-gene disorders to study interactions across many genes, aiming to understand how dozens of genes (CEO cited '60 genes') might interact to produce more complex risks. Recombine recently raised capital to support its carrier-screening business and compete with larger incumbents in the space.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2014